




Neogap Therapeutics selected for EIC Soft-landing Programme in Boston

Neogap Therapeutics, a Swedish biotechnology company developing personalised immunotherapy for cancer treatment, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences in Boston, USA. The programme, organised by the European Innovation Council (EIC), aims to support deep tech companies with research-driven technologies and international expansion potential.



**EIC Soft-landing programme
for Healthcare and Life Sciences
9-13 June 2025 - Boston, USA**



The EIC Soft-landing Programme provides business development support and opportunities to connect with investors, academic institutions and life science stakeholders in Boston – a global hub for cancer research and biotechnology. Neogap's combination of AI, bioinformatics and cell biology in developing personalised immunotherapy aligns well with the programme's focus on deep tech companies.

The initiative is part of the EIC's Business Acceleration Services and brings together selected companies from across the EIC network. Neogap has previously received funding through the EIC Accelerator and is now taking part in the Soft-landing Programme as part of its international expansion strategy.

"Being selected for the EIC Soft-landing Programme is a strong validation of the relevance of our technology in a global innovation context. This programme offers us a concrete opportunity to strengthen our presence in the US market and build new relationships," says Samuel Svensson, CEO of Neogap Therapeutics.

The programme includes a preparatory phase during the spring and culminates in an intensive week in Boston from 9–13 June 2025, during which Neogap will showcase its technology to investors and potential partners and join networking sessions with fellow selected European companies.

Neogap is developing pTTL, a personalised cell-based immunotherapy designed to enhance the patient's own T cells to fight solid tumours. The treatment is based on the company's patented technologies PIOR[®] and EpiTCer[®] and is currently being evaluated in a clinical phase I/II study of advanced colorectal cancer.

European
Innovation
Council



Co-funded by
the European Union

Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:

Samuel Svensson, CEO

Email: samuel.svensson@neogap.se

Phone: +46 733 54 21 94

About Neogap Therapeutics

Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR[®] and EpiTCer[®]. PIOR[®] is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer[®] is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit neogap.se and follow Neogap on [LinkedIn](#).